Kornimate/medical-research-clean huggingface dataset:
enhanced detection in glioma excision

Conditions: Glioma

Summary: the purpose of this study is to determine whether use of an ultra-high sensitivity camera with enhanced imaging technology can be used during surgery to detect areas of brain tissue affected by diffuse glioma, a type of brain cancer.


Eligibility criteria:
inclusion criteria: * participant is willing and able to give informed consent for participation in the study. * male or female, aged 18 years or above. * female patients are not pregnant at time of surgery. * patient has consented to craniotomy for suspected glioma of any type with 5-ala infusion. exclusion criteria: • participants are participating in another trial at time of operation

Keywords: 5-aminolevulinic acid (5-ala) malignant glioma tumor resection
comparing cardiac output measurements in critically ill children using uscom and transthoracic echo

Conditions: Critical Illness; Pediatrics

Summary: the purpose of this study is to compare the accuracy and precision of two non-invasive methods of measuring cardiac output in critically ill children (\<18 yrs). the participants will include any patient admitted to pediatric intensive care unit (picu) requiring a trans-thoracic echo (tte) as part of their treatment plan. measurements of intermittent cardiac output will be obtained and compared on participants using standard 2-d tte and ultrasound cardiac output monitor (uscom).


Eligibility criteria:
inclusion criteria: * any unc picu patient \<18 yrs requiring a transthoracic echo (tte) as standard of care. * gestational age \>36 weeks * wt \> 2 kg * written informed parental permission exclusion criteria: * any patient with known unrepaired intracardiac shunt lesion (asd,pda,vsd) * any post operative patient with delayed closure of chest * parental refusal to participate

Keywords: intensive care units pediatric cardiac index doppler ultrasonography
platelet-rich fibrin versus hifu in management of stress urinary incontinence

Conditions: Stress Urinary Incontinence

Summary: aim of the study is to compare effect of high intensity focused ultrasound (hifu) and platelet-rich fibrin in management of stress urinary incontinence. it is a randomized prospective study. after assigning to one of the two groups, patients will undergo relevant treatment. first group will undergo 3 cycles of intravaginal hifu treatment in 6-weeks interval. second group will undergo 3 injections of platelet-rich fibrin under urethra. before the treatment and after 2, 6 and 12 months after treatment is finished patients will be asked to fill questionaries concerning quality of life iciq-ui sf, iciq-luts, pisq12, fsfi. before each treatment cycle patients will be examined and asked to fill daily micturition plan.


Eligibility criteria:
inclusion criteria: * stress urinary incontinence of low grade * separate episodes of urinary incontinence (associated with increase of abdominal pressure) * no cystocoele or cystocoele popq1 * positive cough test when filled bladder exclusion criteria: * popq 2 and more * patients after urogenital operations or radiation * neuromuscular, hematologic, autoimmune, uncontrolled psychiatric diseases * uncontrolled diabetes * pregnancy, lactation * patients undergoing conservative treatment for stress urinary incontinence * asa or other anti-platelet drug intake less than 7 days before and 7 days after procedure * active carcinomas or status less than 5 years after treatment * sepsis * infection in treated region
the clinical significance of peripheral blood t lymphocyte pd-1 expression and t cell subset distribution.

Conditions: Hepatocellular Carcinoma

Summary: providing more theoretical basis for the prediction of the efficacy of advanced hcc and helping select better advantaged population of hcc immunotherapy to maximize the benefits of patients by exploring the relationship between the changes of pd-1 expression in peripheral blood t lymphocytes and the clinical efficacy before and after the use of pd-1 / pd-l1 inhibitors.

exploring the expression of peripheral blood t lymphocyte pd-1 from an immunological perspective as a potential reference marker for selecting immunotherapy in advanced hcc patients, and elucidating the relationship between the level of peripheral blood t lymphocyte pd-1 expression and survival outcomes after receiving immunotherapy. additionally, investigating whether there is consistency between the expression levels of pd-1 and pd-l1 and their impact on patients. furthermore, exploring the correlation between the distribution of t cell subsets and the efficacy of immunotherapy to provide new theoretical evidence for the selection of target populations for immunotherapy and new clinical screening indicators for patient prognosis assessment.

Eligibility criteria:
inclusion criteria: * willing to participate in the clinical study, fully understand and be informed about the study, and sign the informed consent form; * age between 18 and 75 years, male or female; * strictly meet the clinical diagnostic criteria for hepatocellular carcinoma (hcc), confirmed by histology or cytology, with at least one lesion meeting the recist 1.1 criteria on ct or mri examination; * no prior targeted therapy, immunotherapy, or systemic chemotherapy for liver cancer before admission; * child-pugh a liver function; barcelona clinic liver cancer (bclc) stage b or c; * eastern cooperative oncology group (ecog) performance status of 0-1; * normal function of major organs; * expected survival time of at least 12 weeks or more. exclusion criteria: * patients who have not previously received treatment with sintilimab or any other pd-l1 or pd-1 antagonist; * patients with any active autoimmune disease or a history of autoimmune disease, or a history of immunodeficiency; * patients requiring the use of immunosuppressive drugs; * known history of allergy to the formulation of sintilimab or any other component of the antibody formulation; * patients with other malignant tumors.
a common but unknown disease; nave sliding (ns)

Conditions: Navel; Hernia

Summary: the present study is a case series study, conducted to introduce a common disease of abdominal wall which has received less attention in scientific resources. the study population was all patients who following repeated hospital visits did not improve, and for their last try, they visited a traditional clinic, and were diagnosed with umbilical hernia.

background: the present study is conducted to introduce a common disease of abdominal wall which has received less attention in scientific resources. in traditional medicine sources some scholars believe that this condition occurs due to the movement of the abdominal muscle near the umbilicus or nave laterally movement of nave. design: a case series study method: this study was a case series study. the study population was all patients who following repeated hospital visits did not improve, and for their last try, they visited a traditional clinic, and were diagnosed with umbilical hernia during a period of 5 months.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of nave sliding * must be able to provide a complete health history information exclusion criteria: * unwillingness to continue * any unexpected complication of traditional treatment

Keywords: nave sliding abdominal wall defect
changes in bacterial flora among patients with pelvic bedsores: a prospective pilot study

Conditions: Bedsore

Summary: the main objective of this study is to characterize the evolution (over a period of 28 days) of superficial and deep bacterial skin flora in patients with stage 3 or 4 sacral pressure ulcers (bedsores). changes in terms of pathogenic, potentially pathogenic and non-pathogenic bacterial species at the intra-individual and population levels.

the secondary objectives of this study are: a. to compare bacterial communities collected from superficial versus deep samples of stage 3 or 4 sacral bedsores using metagenomics and standard culturing methods. b. to characterize the evolution of digestive bacterial flora in the same patients over a period of 28 days. changes in terms of pathogenic, potentially pathogenic and non-pathogenic will be described, as well as the appearance of resistance phenotypes. c. to characterize the evolution of urinary bacterial flora in the same patients over a period of 28 days. changes in terms of pathogenic, potentially pathogenic and non-pathogenic will be described, as well as the appearance of resistance phenotypes.

Eligibility criteria:
inclusion criteria: * the patient was correctly informed about study implementation, its objectives, constraints and patient rights * the patient must have given his/her informed and signed consent * the patient must be insured or beneficiary of a health insurance plan * the patient is available for 28 days of follow-up * the patient has one or more pelvic pressure ulcers (bedsores)(stage 3 or 4 only). note: patients with bedsores of varying stage will be included for the wound corresponding to the highest stage. if the patient has multiple bedsores of the same stage, the deepest wound will be selected. * the patient requires a modern wound dressings (i.e. not tulle or gauze) without added bactericidal or antibiotic elements * the patient is hospitalized ant the propara neurological rehabilitation center (montpellier, france) * the patient has not received antibiotics in the last 14 days. exclusion criteria: * the patient is participating in another study, or has participated in another study in the last 3 months * the patient is in an exclusion period determined by a previous study * the patient is under judicial protection, under tutorship or curatorship * the patient refuses to sign the consent * it is impossible to correctly inform the patient * the patient is pregnant, parturient, or breastfeeding * the patient is already included in the present study * the patient has sacral pressure ulcers of only stages 1 or 2, or does not have a sacral pressure ulcer * patient under curative anticoagulation * patient who received antibiotics within 14 days before inclusion (however, after inclusion, the patient can be treated with antibiotics if necessary)

Keywords: bedsore bacteria colonization ecology
da-edoch14-r in poor-prognosis diffuse large b-cell lymphoma

Conditions: Diffuse Large B-Cell Lymphoma (DLBCL)

Summary: poor prognosis dufuse large b-cell lymphoma (dlbcl) represents 50% of all dlbcl with overall cure rates ranging from 50-60% with modern dose-dense immunochemotherapy regimens such as r-chop14. using an alternative strategy, as infusional and dose-adjusted r-epoch, the investigators have shown an 83% of complete responses (cr), with an estimated 5-year overall survival (os) rate of 75% (garcía-suárez et al. british journal of haematology 2007, 136:276). despite this improvement in outcome, the search for new treatment strategies should continue. therefore, compared with prior r-epoch the investigators decided to investigate whether the introduction of dexamethasone (40 mg iv on days 1-5) in place of prednisone (based upon data which demonstrated that the former was associated with enhanced central nervious system penetration) and the reduction of treatment intervals from 3 to 2 weeks would be feasible and might improve the outcome in this group of patients.

medication, dose and method for administration: * rituximab: 375 mg/m2, endovenous, according to the protocol of the service, day 1 (except in the first cycle, in which it will be on day 5). * etoposide: 50 mg/m2/day, in continuous 24-hour infusion, days 1 to 4. * adriamycin: 10 mg/m2/day, in continuous 24-hour infusion of, days 1 to 4. * vincristine: 0.4 mg/m2/day, in continuous 24-hour infusion, days 1 to 4 * dexamethasone: 40 mg, endovenous, days 1 to 5. followed by prednisone 30 mg (day +6), 20 mg (day +7), and 10 mg (day +8). * cyclophosphamide: 750 mg/m2, endovenous, in 30 minutes, day 5, after ending the continuous infusion of adriamycin, etoposide and vincristine. * mesna (if the dose of cyclophosphamide is \> 1 g/m2

Eligibility criteria:
inclusion criteria: * signing the informed consent. * histology: diffuse large b-cell lymphoma de novo (primary mediastinal b-cell lymphomas will be included provided that they have a mass greater than 7 cm in larger diameter) and follicular nhl grade 3b. * aaipi: 2-3. * age: between 18 and 70 years. * general condition (ecog/who): proper organic function, defined by: fevi ≥ 40%, serum creatinine \< 150 µmol/l, serum bilirubin \< 30 µmol/l, control of other medical conditions such as: infection, leukocytes ≥ 3.5 x 109/l and platelets ≥ 100 x 109/l (except if they are caused by lymphomatous infiltration of bone marrow or of the spleen). exclusion criteria: * hiv-positive. * pregnancy or breastfeeding. * serious disease compromising the performance of the therapeutic regimen. * recent history of another malignant disease (except skin cancer different from melanoma or carcinoma in-situ of the cervix), prior radiotherapy or chemotherapy, history of indolent lymphoma. * cns infiltration at diagnosis.

Keywords: poor-prognosis diffuse large b-cell lymphoma dose-adjusted r-edoch-14 rituximab age-adjusted ipi toxicity
the efficacy and safety of a latest dural substitute

Conditions: Cerebrospinal Fluid Leak

Summary: this prospective, multi-center, randomized, parallel-controlled clinical trial was designed to evaluate the efficacy and safety of lyoplant onlay in repairing cerebral dura mater. duraform was regarded as the control group. a total of 80 patients were randomized into experimental and control group (1:1).data were collected on complications resulting in csf leaks, surgical site infections, instrument performance parameterized other neurological complications within 30 days. surgeons also provided data on the ease of use of the dural sealing techniques, as well as preparation and application times. the above-mentioned date were used to evaluate the efficacy and safety of lyoplant onlay .


Eligibility criteria:
inclusion criteria: * any patient between the ages of 18 and 75 years scheduled for elective cranial surgery involving a dural incision. * dural defects and surgical incision was classifed as level 1 exclusion criteria: * local or systemic infection. * patients with known allergy to equipment components * a history of traumatic head injury * a compromised immune system or autoimmune disease * patients who should not participate based on the surgeon's opinion * patients participating in any other drug or device trial. * expected survival time \<12 months * underwent chemoradiotherapy 3 months before randomization * uncontrolled diabetes and malignant tumor * women who were pregnant, lactating, or wished to become pregnant during the study;

Keywords: dura mater cerebrospinal fluid leak
tracking our lives study

Conditions: Mental Health Wellness 2; Health Behavior; Eating Disorders

Summary: college women are at risk for eating disorders, which have profound health impacts. cross-sectional studies have shown that the use of dietary self-monitoring is associated with eating disorder risk among college students. however, causality cannot be established with cross-sectional studies. this study utilizes a randomized controlled trial design to examine how the use of a popular dietary self-monitoring smartphone application impacts college females' well-being, including eating disorder risk. we hypothesize those who are randomized to dietary self-monitoring will have a greater increase in eating disorder risk compared to the control group.


Eligibility criteria:
inclusion criteria: * university of michigan ann arbor undergraduate student * daily access to a smartphone * female gender * at least 18 years of age * fluent in english exclusion criteria: * self-reported history of any medical condition that impacts the types or amount of food eaten * self-reported recent use of dietary self-monitoring * self-reported history of an active or past eating disorder * eating disorder examination questionnaire short form (ede-qs) score ≥ 2, indicating high eating disorder risk
combined spinal- epidural anesthesia in patients with dilated cardiomyopathy

Conditions: Cardiomyopathies

Summary: this study was conducted on 24 patients who have ischemic dilated cardiomyopathy, underwent non cardiac surgery in the lower half of the body under the effect of combined spinal epidural anesthesia at assiut university hospital. intraoperative hemodynamic monitoring including invasive blood pressure, heart rate, and cvp was established, in addition to pre and postoperative, 12 lead ecg, echocardiography, and venous sampling for brain natriuretic peptide measurement were done . this study tried to assess the safety of this anesthetic technique on such group of cardiac patients along over the hospital stay period and up to 6 months postoperatively, in addition to the predictability of brain natriuretic peptide as a cardiac biomarker regarding to the major adverse cardiac events and cardiac mortality for these group of patients .

dilated cardiomyopathy (dcm) is characterized by ventricular dilatation and impaired systolic cardiac function. anesthetic management, of patients with cardiomyopathy with reduced systolic function, is challenging and may be associated with high mortality. objective: the purpose of this study was to evaluate the hemodynamic effects of combined spinal epidural anesthesia (csea) in patients with dilated cardiomyopathy, underwent vascular surgery in the lower half of the body, in addition to assess the safety of this anesthetic technique in the early postoperative period. method: after approval by local research ethics committee of the faculty of medicine, and informed written consent obtained from all patients, 24 patients having dilated cardiomyopathy, subjected to vascular surgery in the lower half of the body under csea. the effects of csea on hemodynamics; ibp, hr and cvp (measured at base line and then every 10 min), in addition to cardiac complications during the hospital stay period were studied.

Eligibility criteria:
inclusion criteria: * 24 patients cardiomyopathy dcm underwent infra-inguinal vascular surgery under the effect of combined spinal epidural technique were included in a prospective trial single center observational study. exclusion criteria: * patients with significant fluid and electrolyte imbalance, major arrhythmias or heart failure or unstable angina, systolic blood pressure at rest \ 2.0 mg /dl, and patients who required emergency surgery were excluded from the study.
evaluation of clinical outcomes after the use of systane® hydration

Conditions: Dry Eye

Summary: the purpose of this study is to compare systane® hydration to hyabak 0.15% based on total ocular surface staining scores (toss) at day 42.

subjects will first be dispensed preservative-free 0.9% saline eye drops (saline eye drops) to be used during the run-in phase between screening visit and day 0 (visit 1). subjects who qualify will be randomized in a 1:1 manner to receive either treatment with systane® hydration lubricant eye drops or hyabak 0.15% eye drops.

Eligibility criteria:
inclusion criteria: * willing and able to attend all study visits; * use of non-bak (benzalkonium chloride) artificial tears at least once a day, for at least 3 months prior to screening visit; * diagnosis of dry eye (by a health care professional) for at least 3 months prior to screening visit; * other protocol-defined inclusion criteria may apply. exclusion criteria: * women of childbearing potential who are pregnant or breast feeding; * any hypersensitivity to the use of the study products or an allergy to any ingredient(s) contained within study products; * ocular abnormalities in either eye that could adversely affect the safety or efficacy outcome; * active ocular infection (bacterial, viral, or fungal) or active inflammation not associated with dry eye; * use of chronic systemic medications: (prescription, over the counter, vitamins/supplements) on a stable dose for less than 30 days prior to screening visit, or any anticipated change in dosing regimen during the course of the study; * history of ocular or intraocular surgery or serious ocular trauma in either eye within 6 months prior to screening visit; * any medical condition (systemic or ophthalmic) that may, in the opinion of the investigator, preclude the safe administration of study products or safe participation in the study; * use of any topical ocular over-the-counter or prescribed medications in either eye (with the exception of artificial tears/gels/ lubricants) 2 weeks prior to screening visit; * contact lens use within 2 weeks prior to screening visit and unwilling to avoid contact lens use during the course of the study; * unwilling to avoid the use of additional artificial tears (other than the study products) throughout the study; * other protocol-defined exclusion criteria may apply.
ropi study : ropivacaine interest in postsurgical pain after mastectomy

Conditions: Pain After Mastectomy

Summary: after surgery for breast cancer, the prevalence of chronic pain is estimated between 20 and 68%. they begin after surgery and may persist until more than 6 months. they respond poorly to opioid analgesics impair the quality of life. among the different postoperative analgesic techniques used, the use of a local anesthetic infiltration continues catheter has advantages including improving the quality of analgesia, with a significant decrease in average of vas (scale visual analogue), a decrease in morphine consumption, improving the quality of life of patients. our study aims to evaluate the effectiveness of a continuous local anesthetic infiltration in the control of postoperative pain after mastectomy.


Eligibility criteria:
inclusion criteria: age\> 18 years * asa i-ii, who 0-1 * mastectomy alone, mastectomy + ggs + mastectomy ca * no previous history of chronic pain requiring regular intake of analgesics or long-term * failure to take opioids within 30 days before surgery exclusion criteria: * long-term treatment analgesic or taking opioids within 30 days before surgery * concurrent treatment with a drug test, participation in another therapeutic clinical trial within \<30 days * proven allergy to local anesthetics of the amide * skin inflammation * sepsis local * kidney failure, liver failure, severe or poorly controlled diabetes * inability to respond to the assessment of pain using a visual analogue scale (vas) or a numerical scale (fr). * mastectomy with immediate breast reconstruction

Keywords: ropivacaine, pain, mastectomy
features and outcomes of patients with reactive arthritis

Conditions: Arthritis

Summary: the aim of this study is to assess the incidence and the clinical and therapeutic characteristics of reactive arthritis and to compare them with those of a historical cohort. we hypothesised that improved hygiene together with prevention and treatment of sexually transmitted infections may have decreased the incidence of reactive arthritis.


Eligibility criteria:
inclusion criteria: * reactive arthritis diagnosed in one of the two rheumatology departments from centre hospitalier lyon sud or besançon exclusion criteria: * presence of other known causes of arthritis, such as other defined spondyloarthritides, septic arthritis, lyme disease, microcrystalline arthritis or rheumatoid arthritis